Klaus Orlinger
VP RESEARCH
pediatric
Hookipa Biotech
Austria
Biography
As VP Research at Hookipa, Dr. Klaus Orlinger is responsible for generation and characterization of prophylactic and therapeutic vaccines / immunotherapy candidates. He developed the HB-101 vaccine candidate of Hookipa’s cytomegalovirus vaccine
Research Interest
Vaccinaition, Pediatric & Neonatal Health Care
